Wire
Wedbush Adjusts Fennec Pharmaceuticals PT to $16 From $13, Maintains Outperform Rating
Wedbush Adjusts Fennec Pharmaceuticals PT to $16 From $13, Maintains Outperform Rating
$FENC
$FENC
3 stories mentioning FENCUpdated 41d ago
Every FINWIRES story that references FENC, newest first.
What are analysts saying about FENC?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
What's the latest news on FENC?
Mining & Metals
Fennec Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting
Fennec Pharmaceuticals (FRX.TO, FENC) after the close Tuesday said four abstracts evaluating PEDMARK (sodium thiosulfate) were accepted to the 2026 ASCO annual meeting, May 29 to June 2 in Chicago. Two items are poster presentations and two are abstract-only publications.According to the statement, PEDMARK is approved for pediatric patients one month and older and carries a NCCN 2A recommendation for adolescent and young adult patients. Full abstracts will be available on the ASCO website on May 21.The company's shares closed unchanged at $9.00 on Toronto Stock Excahnge on Tuesday.
$FENC$FRX.TO
Mining & Metals
Wedbush Refines Fennec Pharmaceuticals Estimates Ahead of Q1 Earnings
Wedbush is refining its its 2026 estimates for Fennec Pharmaceuticals (FRX.TO) ahead of the company reporting its fiscal first-quarter results."While we believe underlying demand trends remain intact, we are refining our 2026 estimates to reflect anticipated seasonality and the near-term impact of recent commercial reinvestment. Given onboarding and ramp dynamics, we do not expect meaningful contribution from new hires until 2H26 and anticipate limited sequential growth in 1H26," writes analyst David Nierengarten, who is maintaining an outperform and US$13.00 price target on the stock.Nierengarten forecasts first-quarter Pedmark revenue of US$13. million (~flat q/q), with a similar setup in the second quarter, before growth reaccelerates in the second half of the year as sales force productivity improves and the adolescent and young adult (AYA) penetration builds. (Pedmark is an injection used to lower the risk of hearing-loss induced by cisplatin chemotherapy)For fiscal 2026, Nierengarten expects Pedmark revenue of ~US$62 million (+39% y/y), with the back-half weighting driven by incremental contribution from new commercial hires."We continue to view Pedmark as a durable growth asset with a clear path to re-acceleration in 2H26, with FENC on track to achieve cash flow positivity in 2026, supporting a constructive outlook on shares."Price: $8.75, Change: $+0.10, Percent Change: +1.16%
$FENC$FRX.TO
